We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?
Read MoreHide Full Article
Key Takeaways
Collegium Pharmaceutical will report Q4 and full-year 2025 earnings results on Feb. 26.
COLL saw rising Jornay PM share and prescribers in Q3 and the same trend is expected to continue in Q4.
COLL expects 2026 net product revenues of $805-$825M and Jornay PM sales to be $190-$200M.
Collegium Pharmaceutical (COLL - Free Report) is scheduled to report its fourth-quarter and full-year 2025 results on Feb. 26, before the opening bell. The company’s commercial portfolio currently comprises Jornay PM, which is approved for treating attention deficit hyperactivity disorder (“ADHD”) as well as its marketed pain-management drugs, Belbuca, Xtampza ER, Nucynta IR and Nucynta ER (collectively the “Nucynta Products”).
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $208.6 million, while the same for earnings is $2.19 per share.
In the past six months, shares of Collegium Pharmaceutical have risen 18% against the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up before the announcement.
Factors Likely to Influence COLL's Q4 Results
Collegium Pharmaceutical’s revenues in the to-be reported quarter are likely to have been driven by its lead growth driver Jornay PM (methylphenidate HCl), reflecting strong brand fundamentals and ongoing commercial efforts.
In the last reported quarter, the company delivered growth in Jornay prescriptions, market share and prescribers, a trend most likely to have continued in the fourth quarter.
The company remains focused on driving near- and long-term growth for Jornay PM. It is also working on expanding its sales force to increase awareness and adoption among prescribers. We expect management to provide more updates on the same on the upcoming earnings call.
The September 2024 acquisition of Ironshore Therapeutics added Jornay PM, a central nervous system stimulant for ADHD, to COLL’s commercial portfolio.
Collegium Pharmaceutical is also making good progress with its unique and differentiated portfolio of pain medicines. In the last reported quarter, the combined quarterly revenues from its pain portfolio reached an all-time high. Increasing sales of its pain medicines are likely to have aided COLL’s revenues in the fourth quarter.
The company remains committed to maximizing revenues from its pain portfolio in 2026 through a combination of driving demand and enhancing the profitability of each brand. Investors will be keen to get more updates on the same on the upcoming earnings call.
Last month, the company announced full-year guidance for 2026. Net product revenues are expected to be in the range of $805-$825 million, while Jornay PM net revenues are expected to be in the range of $190-$200 million.
Adjusted operating expenses are likely to have increased year over year in the to-be-reported quarter, reflecting higher commercialization costs for Jornay and other investment costs.
COLL’s Earnings Surprise History
Collegium Pharmaceutical has an excellent earnings surprise history. The company beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 10.63%. In the last reported quarter, COLL came up with an earnings surprise of 19.68%.
Collegium Pharmaceutical, Inc. Price and EPS Surprise
Our proven model does not predict an earnings beat for Collegium Pharmaceutical this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: COLL has an Earnings ESP of -2.43% as the Most Accurate Estimate stands at $2.14 per share and the Zacks Consensus Estimate is pegged at $2.19 per share.
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +68.89% and sports a Zacks Rank #1 at present.
Castle Biosciences’ stock has risen 70.2% in the past six months. CSTL beat earnings estimates in three of the last four reported quarters and missed once, delivering an earnings surprise of 66.11%, on average. Castle Biosciences is scheduled to report fourth-quarter results on Feb. 26.
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +1.89% and a Zacks Rank #2 at present.
Amneal Pharmaceuticals’ stock has risen 57.8% in the past six months. AMRX beat earnings estimates in three of the last four reported quarters and missed once, delivering an earnings surprise of 22.42%, on average. Amneal Pharmaceuticals is scheduled to report fourth-quarter results on Feb. 27.
Axsome Therapeutics (AXSM - Free Report) has an Earnings ESP of +43.57% and a Zacks Rank #3 at present.
Shares of AXSM have rallied 57.9% in the past six months. Axsome Therapeutics beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 8.47%. Axsome Therapeutics is slated to report fourth-quarter results on Feb. 23.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?
Key Takeaways
Collegium Pharmaceutical (COLL - Free Report) is scheduled to report its fourth-quarter and full-year 2025 results on Feb. 26, before the opening bell. The company’s commercial portfolio currently comprises Jornay PM, which is approved for treating attention deficit hyperactivity disorder (“ADHD”) as well as its marketed pain-management drugs, Belbuca, Xtampza ER, Nucynta IR and Nucynta ER (collectively the “Nucynta Products”).
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $208.6 million, while the same for earnings is $2.19 per share.
In the past six months, shares of Collegium Pharmaceutical have risen 18% against the industry’s decline of 3.4%.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up before the announcement.
Factors Likely to Influence COLL's Q4 Results
Collegium Pharmaceutical’s revenues in the to-be reported quarter are likely to have been driven by its lead growth driver Jornay PM (methylphenidate HCl), reflecting strong brand fundamentals and ongoing commercial efforts.
In the last reported quarter, the company delivered growth in Jornay prescriptions, market share and prescribers, a trend most likely to have continued in the fourth quarter.
The company remains focused on driving near- and long-term growth for Jornay PM. It is also working on expanding its sales force to increase awareness and adoption among prescribers. We expect management to provide more updates on the same on the upcoming earnings call.
The September 2024 acquisition of Ironshore Therapeutics added Jornay PM, a central nervous system stimulant for ADHD, to COLL’s commercial portfolio.
Collegium Pharmaceutical is also making good progress with its unique and differentiated portfolio of pain medicines. In the last reported quarter, the combined quarterly revenues from its pain portfolio reached an all-time high. Increasing sales of its pain medicines are likely to have aided COLL’s revenues in the fourth quarter.
The company remains committed to maximizing revenues from its pain portfolio in 2026 through a combination of driving demand and enhancing the profitability of each brand. Investors will be keen to get more updates on the same on the upcoming earnings call.
Last month, the company announced full-year guidance for 2026. Net product revenues are expected to be in the range of $805-$825 million, while Jornay PM net revenues are expected to be in the range of $190-$200 million.
Adjusted operating expenses are likely to have increased year over year in the to-be-reported quarter, reflecting higher commercialization costs for Jornay and other investment costs.
COLL’s Earnings Surprise History
Collegium Pharmaceutical has an excellent earnings surprise history. The company beat estimates in each of the trailing four quarters, delivering an average earnings surprise of 10.63%. In the last reported quarter, COLL came up with an earnings surprise of 19.68%.
Collegium Pharmaceutical, Inc. Price and EPS Surprise
Collegium Pharmaceutical, Inc. price-eps-surprise | Collegium Pharmaceutical, Inc. Quote
Earnings Whispers for COLL
Our proven model does not predict an earnings beat for Collegium Pharmaceutical this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: COLL has an Earnings ESP of -2.43% as the Most Accurate Estimate stands at $2.14 per share and the Zacks Consensus Estimate is pegged at $2.19 per share.
Zacks Rank: COLL currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Castle Biosciences (CSTL - Free Report) has an Earnings ESP of +68.89% and sports a Zacks Rank #1 at present.
Castle Biosciences’ stock has risen 70.2% in the past six months. CSTL beat earnings estimates in three of the last four reported quarters and missed once, delivering an earnings surprise of 66.11%, on average. Castle Biosciences is scheduled to report fourth-quarter results on Feb. 26.
Amneal Pharmaceuticals (AMRX - Free Report) has an Earnings ESP of +1.89% and a Zacks Rank #2 at present.
Amneal Pharmaceuticals’ stock has risen 57.8% in the past six months. AMRX beat earnings estimates in three of the last four reported quarters and missed once, delivering an earnings surprise of 22.42%, on average. Amneal Pharmaceuticals is scheduled to report fourth-quarter results on Feb. 27.
Axsome Therapeutics (AXSM - Free Report) has an Earnings ESP of +43.57% and a Zacks Rank #3 at present.
Shares of AXSM have rallied 57.9% in the past six months. Axsome Therapeutics beat on earnings in three of the trailing four quarters and missed in one, delivering an average surprise of 8.47%. Axsome Therapeutics is slated to report fourth-quarter results on Feb. 23.